Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome.

Feng Lin
Thomas E Ichim
Sandeep Pingle
Lawrence D Jones
Santosh Kesari

Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute/Pacific Neuroscience Institute, 2200 Santa Monica Boulevard, Santa Monica, CA, 90404, USA

See next page for additional authors

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications

Part of the Infectious Disease Commons, and the Pulmonology Commons

Recommended Citation
Lin, Feng; Ichim, Thomas E; Pingle, Sandeep; Jones, Lawrence D; Kesari, Santosh; and Ashili, Shashaanka, "Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome." (2020). Articles, Abstracts, and Reports. 3979. https://digitalcommons.psjhealth.org/publications/3979

This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org.
Authors
Feng Lin, Thomas E Ichim, Sandeep Pingle, Lawrence D Jones, Santosh Kesari, and Shashaanka Ashili
Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome

Feng Lin, Thomas E Ichim, Sandeep Pingle, Lawrence D Jones, Santosh Kesari, Shashaanka Ashili

ORCID number: Feng Lin 0000-0001-7662-423X; Thomas E Ichim 0000-0001-5661-374X; Sandeep Pingle 0000-0003-0124-499X; Lawrence D Jones 0000-0002-8706-2014; Santosh Kesari 0000-0003-3772-6000; Shashaanka Ashili 0000-0001-6335-0954.

Author contributions: All authors contributed equally to this paper in conception, literature review and analysis, drafting, critical revision and editing, and approval of the final version.

Conflict-of-interest statement: No conflict of interest to report.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Abstract
Coronavirus disease 2019 (COVID-19), a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), is growing at an exponential rate worldwide. Manifestations of this disease are heterogeneous; however, advanced cases often exhibit various acute respiratory distress syndrome-like symptoms, systemic inflammatory reactions, coagulopathy, and organ involvements. A common theme in advanced COVID-19 is unrestrained immune activation, classically referred to as a “cytokine storm”, as well as deficiencies in immune regulatory mechanisms such as T regulatory cells. While mesenchymal stem cells (MSCs) themselves are objects of cytokine regulation, they can secrete cytokines to modulate immune cells by inducing anti-inflammatory regulatory Treg cells, macrophages and neutrophils; and by reducing the activation of T and B cells, dendritic and nature killer cells. Consequently, they have therapeutic potential for treating severe cases of COVID-19. Here we discuss the unique ability of MSCs, to act as a “living anti-inflammatory”, which can “rebalance” the cytokine/immune responses to restore equilibrium. We also discuss current MSC trials and present different concepts for optimization of MSC therapy in patients with COVID-19 acute respiratory distress syndrome.

Key Words: Mesenchymal stem cells; SARS-CoV-2; COVID-19; Cytokine storm; Acute respiratory distress syndrome; Immunomodulation

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
INTRODUCTION

The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) are caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with few effective treatments currently available. SARS-CoV-2 along with SARS-CoV and middle east respiratory syndrome coronavirus are coronaviruses that have caused significant human morbidity and mortality. We are currently in the middle of a SARS-CoV-2 global pandemic. As of August 7, 2020, based on a Johns Hopkins University Coronavirus Resource Center Report, there have been at least 19.4 million confirmed cases worldwide, with at least 722706 deaths, and a mortality rate reaching approximately 3.7%. In the United States alone, approximately 5 million people are infected resulting in 161810 deaths and a mortality rate of 3.3%. COVID-19 infection of the lungs leads to extraordinary intensive care unit resource utilization and mortality.

One of the ways COVID-19 produces morbidity and mortality is by severely impairing lung function, causing a condition called acute respiratory distress syndrome (ARDS). This is characterized by a rapid onset of cytokine storm widespread lung inflammation, and sepsis-like conditions. Currently there is no effective anti-viral treatment for COVID-19. However, a few therapeutic strategies have been tested in the clinic or in trials for the treatment of patients with COVID-19. The anti-viral remdesivir can reduce death risk of severe COVID-19 patients as much as 62% when compared with standard care alone. Other anti-viral drugs such as but not limited to lopinavir-ritonavir, favipiravir, chloroquine and hydroxychloroquine have been proposed to treat COVID-19. Many of these anti-viral agents are currently being tested in clinical trials. Anti-inflammatory drugs such as dexamethasone were found to have beneficial effects in critically ill COVID-19 patients. Additionally, tocilizumab and siltuximab are interleukin-6 inhibitors being studied as therapeutics in critically ill patients with severe respiratory failure and elevated serum IL-6. The immunomodulatory functions of mesenchymal stem cells (MSCs) have been well documented in recent years. While MSCs themselves are objects of cytokine regulation, they can secrete cytokines to modulate immune cells by inducing anti-inflammatory regulatory Treg (T) cells, macrophages and neutrophils; and by reducing the activation of T and B cells, dendritic and nature killer (NK) cells. Consequently, they have therapeutic potential for treating severe cases of COVID-19.

Preclinical and clinical studies have shown that MSCs work in reversing ARDS caused by other conditions such as influenza virus infection, or sepsis. For example, MSCs derived from adipose[25], bone marrow[26-29], placental[30], amniotic membrane[31-33], umbilical cord[34-35], menstrual blood[36] and lung[37-39] origin, as well as conditioned media[40-41], have demonstrated reduction of pulmonary injury, and neutrophil accumulation. Early clinical trials[42-43] have shown safety of systemic infusions and bronchial instillations of MSCs for treating ARDS and other pulmonary complications. Most recently small studies[44-45] have also suggested that MSCs can be effective in COVID-19 ARDS; however, these approaches have not been well validated. In this review, we discuss the immunomodulatory effects of stem cells and the role of MSCs as potential therapeutic options for cytokine storm and/or ARDS in COVID-19.
COVID-19 AND ITS PATHOLOGY

SARS-CoV-2 enters host cells through the angiotensin converting enzyme 2 (ACE2) receptor. ACE2 expression was found to be high in the lung, heart, ileum, kidney and bladder\[51]. ACE2 is highly expressed on the apical side of lung epithelial cells in the alveolar space, which is how SARS-CoV-2 virus can likely enter and destroy these cells. This is probably why early lung injury was often seen in the distal airway. The issue now becomes in what way does the immune system respond to viral infection in the lung. Innate immunity in the airway mainly includes epithelial cells, alveolar macrophages and dendritic cells. They fight against the virus until adaptive immunity is initiated. T cell mediated responses are initiated by antigen presentation via dendritic cells and macrophages. CD4+ T cells activate B cells to promote the production of virus-specific antibody CD8+ T cells which can kill virus infected cells. Approximately 80% percent of patients with COVID-19 are asymptomatic or experience only mild symptoms such as fever, dry cough and shortness of breath. However, some patients deteriorate quickly and develop ARDS\[52]. Patients with severe diseases were reported to have increased plasma levels of proinflammatory cytokines, including IL-6, IL-8, IL-10, GM-CSF, macrophage inflammatory protein 1-alpha, and TNF-alpha\[53].

Information regarding the pathological findings in COVID-19 is still limited, although several reports on this topic have been published recently. Xu et al\[54]\ reported one case where the patient presented 15 d of symptoms. Biopsy samples from both lungs showed bilateral diffuse alveolar damage\[55] with cellular fibromyxoid exudates and hyaline membrane formation, indicating ARDS in both lungs. Noteworthy is the observation that the pathological features of COVID-19 greatly resemble those seen in SARS and middle east respiratory syndrome coronavirus infections\[56,57]. In addition, over-activation of T-cells was manifested by an increase of Th17 and high cytotoxicity of CD8 T cells, partially accounting for the severe immune injury in the patient.

Tian et al\[58]\ described the early histopathological features in two patients who underwent postmortem for lung cancer but were later discovered to have had COVID-19 upon resection. The results of the lung evaluation from the two patients exhibited only nonspecific histologic changes, including edema, proteinaceous exudate, hyperplastic pneumocytes, patchy inflammation, and multinucleated giant cells with no hyaline membrane. Given that the two patients were asymptomatic from COVID-19 at the time of postmortem, they were likely only in the early stages of acute lung injury from the infection\[59]. Tian et al\[60]\ also conducted another postmortem study of four COVID-19 patients with a minimum of 15 days of symptoms, demonstrated ARDS in all biopsies.

Two COVID-19 autopsies on the lungs of a 77-year-old man revealing diffuse alveolar damage, the most common histopathologic correlation with ARDS, and on the lungs of a 42-year-old man presenting no evidence of diffuse alveolar damage/ARDS\[61]. Magro et al\[62]\ demonstrated in a report of five cases that diffuse alveolar damage was not prominent with the presentation of hyaline membranes, inflammation, and type II pneumocyte hyperplasia, all hallmarks of classic ARDS. These pulmonary findings were accompanied by significant deposits of terminal complement components C5b-9, C4d, and mannose binding lectin-associated serine protease 2, in the microvasculature, consistent with sustained, systemic activation of the alternative and lectin-based complement pathways. There was co-localization of COVID-19 spike glycoproteins with C4d and C5b-9 in the interalveolar septa and the cutaneous microvasculature of two cases examined. This indicated the pathophysiologic importance of complement in COVID-19. The results suggest that at least a subset of severe COVID-19 infection involves a catastrophic, complement-mediated thrombotic microvascular injury syndrome with sustained activation of the alternative and lectin-based cascades, possible pathways apart from virus spike protein engagement.

In general, ARDS is a common manifestation of cytokine storms and as well could be the cause of death in many COVID-19 patients, although other mechanisms may also be involved. A better understanding of COVID-19 patients’ underlying pathogenesis will pave the way for formulating a timely therapeutic strategy to reduce mortality.
MSCs are fibroblast-like and multipotent stromal cells. Human MSCs are positive for a number of cell surface markers including CD73, CD44, CD90, and CD105 and negative for the hematopoietic markers of CD34, CD45 and HLA-DR[6]. MSCs are traditionally isolated from bone marrow, and a variety of fetal, neonatal and adult tissues, including cord blood, peripheral blood, fetal liver and lung, adipose tissue, compact bone, dental pulp, dermis, endometrial, human islet, adult brain, skeletal muscle, amniotic fluid, synovium, and the circulatory system[6,8]. MSCs can differentiate into a variety of cell types of mesodermal origin, including osteoblasts, chondrocytes, cardiomyocytes, neural cells, smooth muscle cells and adipocytes[8,9]. MSCs are likely the only stem cell type that possesses both regenerative and immunomodulatory capabilities. Consequently, they have been used widely in the treatment of many degenerative and inflammatory diseases.

One property that greatly increases the value of MSCs in therapeutic applications is their ability to modulate immune responses. MSCs can exert their immunomodulatory function by producing many molecules having immunomodulatory effects, these include prostaglandin E2 (PGE2)[9], nitric oxide[10], indolamine 2,3-dioxigenase (IDO)[11], transforming growth factor beta[12], IL-6[13], hemoxygenase-1[14], leukocyte inhibitory factor[15], HLAG5 and chemokines[16], PDL1/2[17] and other surface markers-FasL[18]. MSCs can escape the immune system because bone marrow derived MSCs (BM-MSCs) are not recognized by NK cells as they lack expression of HLA Class I surface markers. They also lack expression of HLA Class II antigens, which is desirable for transplantation applications.

The immunosuppressive activity of MSCs is well described, with recent reports providing some mechanistic insights into key soluble factors and receptors. Programmed death-ligand 1/CD274 also known as B7 Homolog 1 (B7-H1) has been shown to be expressed in cultured MSCs and is strongly upregulated following IFN-γ stimulation. Combination therapy using rapamycin and MSCs induced immune tolerance to allografts, but monoclonal antibodies against B7-H1 were shown to abrogate this tolerance leading to allograft rejection[8]. The immunomodulatory effects of MSCs were mediated in part through upregulation of regulatory immune cells including CD4+CD25+FoxP3+ T cells[9,10] and tolerogenic dendritic cells[11] and a decrease in alloantibody levels. MSCs that expressed B7H1 may also induce the apoptosis of activated T-cells as a co-culture of CD4+CD25- T cells with MSCs resulting in significant upregulation of programmed cell death-1 receptor (PD-1) on activated T cells[12]. Similar results were reported by Chinnadurai et al[13] who further examined the role of IFN-γ in the “licensing” of MSCs to inhibit the proliferation of activated T cells[14]. Both MSCs and IFN-γ licensed MSCs inhibited T-cell proliferation; however, only IFN-γ licensed MSCs significantly inhibited Th1 cytokine (IFN-γ, TNFα and IL-2) production as well as T-cell degranulation. This IFN-γ licensed MSCs inhibitory effect on T-cells is thought to be dependent on IDO[15]; however, Chinnadurai showed that MSC IDO catalytic function is dispensable with regard to MSC driven T-cell inhibition. Chinnadurai et al[16] identified the B7-H1 PD1 pathways as essential effectors in blocking T-cell function. Further complexity was also suggested by a recent report that IFN-γ treatment of MSCs upregulated HLA-DR/Class II MHC after 48 h, and MSCs ability to inhibit T cells through B7-H1 was dependent upon the presence of HLA-DR[17].

MSCs express the adhesion molecules VCAM-1 and ICAM-1, which allow T-lymphocytes to adhere to their surface. Subsequently MSCs can affect them by molecules which have a short half-life. Their effect is in the immediate vicinity of the cell[18]. Examples of such molecules include nitric oxide, PGE2, HGF[19], and activation of receptor PD-1. MSCs reduce T cell proliferation between G0 and G1 cell cycle phases G0[20], and decrease the expression of IFNγ of Th1 cells while increasing the expression of IL-4 of Th2 cells[21]. MSCs also inhibit the proliferation of B-lymphocytes between G0 and G1 cell cycle phases.

A novel mechanism for MSC-induced immunosuppression was recently proposed by Obermajer and colleagues who showed that cells of the Th17 type, predominantly associated with the rejection of allogeneic solid organ grafts, can be directly converted into a regulatory T cell type[22]. The induction of Tregs was preceded by development of a CD11b(hi)Gr1(int) myeloid-derived immunosuppressive cell-mediated Th17. They identified retinoic acid receptor-related orphan receptor γ as a common factor in the differentiation of T and Th17 cells. The identification of a specific subset of T cells IL-17A/Foxp3+ double-positive and ex-IL-17 producing IL-17A-Foxp3+ in this paper argues for direct conversion as the mechanism for MSC-mediated immuno-tolerance. This proposed mechanism where MSC-induced myeloid-derived immunosuppressive
cells act as mediator for immune tolerance without complete immunosuppression may have significant implications for therapeutic applications.

MSCs have an effect on macrophages, neutrophils, NK cells, mast cells and dendritic cells in innate immunity and effector T cells, regulatory T cells, and B cells in adaptive immunity illustrated in Figure 1. In severe COVID-19 patients, their immune responses to SARS-CoV-2 infection are usually over-activated. MSCs are able to exert their anti-inflammatory effect by regulating immune cells and balancing the immune responses. Furthermore, MSCs can migrate to the site of injury, where they polarize through GE2 macrophages into phenotype-2 which is characterized by an anti-inflammatory effect [8-10]. Further, PGE2 inhibits the ability of mast cells to degranulate and produce TNF-α. Proliferation and cytotoxic activity of NK cells are inhibited by PGE2 and IDO. MSCs also reduce the expression of NK cell receptors-NKG2D, Nkp44 and Nkp30[9], MSCs inhibit respiratory flare and apoptosis of neutrophils by production of cytokines IL-6 and IL-8[10]. Differentiation and expression of dendritic cell surface markers is inhibited by IL-6 and PGE2 of MSCs[9]. The immunosuppressive effects of MSCs also depend on IL-10, but it is not certain whether they produce it alone, or only stimulate other cells to produce it[10,11].

MSCS THERAPY FOR INHIBITION OF ACUTE INFLAMMATION AND CYTOKINE STORM

MSCs have been shown to possess a comprehensive and powerful immuno-modulatory function to suppress excessive activation of the immune system, thus promoting endogenous repair by improving the microenvironment. There have been 13 MSCs therapies approved for treating a number of conditions (Table 1) outside of the United States, mainly in the EU, Japan, South Korea and India. Among the conditions, two adipose tissue derived MSC products, Alofisel® and Cupistem®, have been used for complex perianal fistulas in Crohn’s disease. The underlying mechanism of action is the MSC immunomodulatory and anti-inflammatory effects at the inflammation sites. Specifically MSCs impair proliferation of activated lymphocytes and reduce the inflammatory cytokines. Two BM-MSC products, Prochymal® and Temcell® HS, have been used for treating GvHD, due to MSCs immunomodulatory effects.

Preclinical study has demonstrated that MSCs can inhibit the progress of acute inflammation in the lungs and alleviate symptoms of respiratory distress[9]. The feasibility of utilizing MSCs for the treatment of ARDS has been demonstrated in animal models and extracorporeal lung models[93]. MSCs of adipose, bone marrow, placental, amniotic membrane, umbilical cord, menstrual blood, and lung, origin, as well as conditioned media with secreted exosomes, have demonstrated a reduction of pulmonary injury and neutrophil accumulation. In a recent study using a sheep model of ARDS[9], both endobronchial and intravenous administration of bone marrow-derived multipotent adult progenitor cells were effective for the treatment of ARDS.

Additionally, an analysis of 342 systemic infusions and 57 bronchial instillations (204 recipients) of cells of various origins for ARDS and other pulmonary issues demonstrated safety in early human clinical trials[94]. Recently, a study involving two patients with severe refractory ARDS, both showed improvement[95]. Both patients received $2 \times 10^6$ cells per kilogram of body weight. Subsequently, each of the patients improved with resolution of respiratory, hemodynamic, and multiorgan failure. In parallel, a decrease was seen in multiple pulmonary and systemic markers of inflammation, including epithelial apoptosis, alveolar-capillary fluid leakage, proinflammatory cytokines, microRNAs, and chemokines. In vitro studies of the MSCs demonstrated a broad anti-inflammatory capacity, including suppression of T-cell responses and induction of regulatory phenotypes in T cells, monocytes, and neutrophils. Some of these in vitro potency assessments correlated with, and were relevant to, the observed in vivo actions.

RECENT SUCCESS OF MSCS FOR COVID-19 PATIENTS AND CLINICAL TRIALS

Currently, drugs alone or in combination with other therapeutic approaches have not afforded a cure; however a number of investigational drugs in clinical trials, including antivirals such as chloroquine/hydroxychloroquine, remdesivir, immune-based
MSCs: Mesenchymal stem cells; BM-MSCs: Bone marrow derived mesenchymal stem cells; EU: European Union; UC-MSCs: Umbilical cord mesenchymal stem cells; AT-MSCs: Adipose tissue-derived mesenchymal stem cells.

Therapies and adjunctive therapies have shown promise, particularly in mitigating certain systemic markers according to NIH COVID-19 Guidelines. Potential antiviral drugs: remdesivir, chloroquine or hydroxychloroquine, hydroxychloroquine plus azithromycin, lopinavir/ritonavir and other HIV protease inhibitors. Immune-based therapy under evaluation: Convalescent plasma, Immunoglobulins: SAR-CoV-2-specific and non-SAR-CoV-2 specific, MSCs, Corticosteroids, Interferons alpha and beta, IL-1 and IL-6 inhibitors, Kinase inhibitors: Bruton’s tyrosine kinase inhibitors and Janus kinase inhibitors; Adjunctive therapy: antithrombotic therapy, vitamin C and vitamin D, zinc supplementation.

To date, there are over 50 clinical trials using MSCs to treat COVID-19 patients based on the registration in clinicaltrial.gov website, we listed the most relevant studies in Table 2. Umbilical cord MSCs (UC-MSCs), BM-MSCs, AT-MSCs and other MSCs, as well as exosomes from MSCs are used in clinical trials, among them UC-MSCs are the most desirable for treating severely compromised COVID-19 patients due to its rich and extensive source of stem cells, scalable expansion capability, and ability to be allogeneic as low MHC-I expression \[49\]. The dose and delivery times are also varied in different trials. Recent reviews have described the potential for and rationale of using different types of MSCs for treating severe COVID-19 patients to protect alveolar epithelial cells, to reclaim the pulmonary microenvironment, to induce anti-inflammatory macrophages, regulatory T and B cells, and regulatory dendritic cells. In addition, MSCs can inactivate T cells in order to prevent cytokine storm, prevent pulmonary fibrosis and cure lung dysfunction \[101-104\]. Details of MSCs clinical trials for COVID-19 have also been discussed in other reviews \[101,104-106\].

MSCs have been used effectively to treat patients with COVID-19 in recent reports \[50,107,108\]. The underlying processes involve preventing the cytokine storm from occurring as well as reversing the cytokine storm in compromised patients. A total of seven patients with COVID-19 were enrolled in the study \[50\], the results have shown that MSCs significantly improved the functional outcome without observed adverse effects. The pulmonary function and symptoms of these patients were significantly improved in two days after MSC transplantation. Among them, two common and one severe patient recovered and were discharged within 10 d after the treatment. Compared to the placebo control group, the level of TNF-alpha was significantly decreased, and IL-10 increased in the MSCs treatment group. The gene profile showed MSCs were ACE2- and TMPRSS2- which indicate MSCs are free from COVID-19
Table 2 The most relevant clinical trials of mesenchymal stem cell treating COVID-19 patients

| NCT number       | Cell type                          | Cell type   | Phase | Sponsor                                                                 |
|------------------|------------------------------------|-------------|-------|-------------------------------------------------------------------------|
| NCT04490486      | UC-MSCs                            | Allogeneic  | I     | Joshua M Hare, United States                                           |
| NCT04456361      | UC-MSCs                            | Allogeneic  | I     | Instituto de Medicina Regenerativa, Mexico                            |
| NCT04313322      | UC-MSCs                            | Allogeneic  | I     | Stem Cells, Arabia                                                      |
| NCT04288102      | UCs                                | NA          | II    | Beijing 302 Hospital                                                    |
| NCT04346368      | BM-MSCs                            | NA          | I/II  | Guangzhou Institute of Respiratory Disease                              |
| NCT04366232      | Adipose-derived MSCs               | Allogeneic  | I/II  | Andalusian Network for Design and Translation of Advanced Therapies    |
| NCT04273646      | UC-MSCs                            | Allogeneic  | I     | Wuhan Union Hospital, China                                            |
| NCT04349631      | Adipose-derived MSCs               | Autologous  | II    | Hope Biosciences                                                        |
| NCT04339660      | UC-MSCs                            | Allogeneic  | I/II  | Puren Hospital Affiliated to Wuhan University of Science and Technology |
| NCT04366063      | MSCs                               | NA          | II/III| Royan Institute                                                         |
| NCT04352803      | Adipose-derived MSCs               | Autologous  | I     | Regeneris Medical                                                       |
| NCT04355728      | UC-MSCs                            | Allogeneic  | I/II  | Camillo Ricordi                                                         |
| NCT04366271      | UC-MSCs                            | Allogeneic  | II    | Hospital Infantil Universitario Niño Jesús, Madrid, Spain              |
| NCT04348461      | Adipose-derived MSCs               | Allogeneic  | I     | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz       |
| NCT04345601      | BM-MSCs                            | Allogeneic  | I     | Baylor College of Medicine                                              |
| NCT03042143      | UC-MSCs (CD362 enriched)           | Allogeneic  | I/II  | Belfast Health and Social Care Trust                                   |
| NCT04361942      | MSCs                               | Allogeneic  | II    | Red de Terapia Celular                                                  |
| NCT04269525      | UC-MSCs                            | Allogeneic  | II    | Zhi-Yong Peng, Hospital                                                |
| NCT04333638      | UC-MSCs                            | Allogeneic  | I     | Assistance Publique - Hôpitaux de Paris                                |
| NCT04299152      | Cord blood stem cells (CB-SC)      | Allogeneic  | II    | Tianhe Stem Cell Biotechnologies Inc.                                   |
| NCT04341610      | Adipose-derived MSCs               | Allogeneic  | I/II  | Rigshospitalet, Denmark                                                 |
| NCT04276987      | Adipose-MSC-derived exosomes (inhalation) | Allogeneic | I     | Ruijin Hospital                                                         |
| NCT03857841      | BM-MSC-derived extracellular vesicles (UNEX-42) | Allogeneic | I     | United Therapeutics                                                    |

MSC: Mesenchymal stem cells; BM-MSC: Bone marrow derived mesenchymal stem cells; UC-MSCs: Umbilical cord mesenchymal stem cells.

In another case report[71], UC-MSCs were infused into a severely compromised COVID-19 patient. The pulmonary function and symptoms of the patient were significantly improved in 2 d after UC-MSCs transplantation. The patient recovered and was discharged in 7 d after treatment. The percentage and counts of lymphocyte subsets (CD3, CD4, and CD8 T cell) were increased, and the level of IL-6, TNF-α, and C-reactive protein was shown to have significantly decreased after UC-MSCs infusion. After the first infusion of UC-MSCs, the SARS-CoV-2 PCR results of 30 patients (96.8%) became negative after a mean time of 10.7 d (SD, 4.2 d). Laboratory parameters tended to improve after UC-MSCs therapy compared to the status before treatment, including elevated lymphocyte count, decreased C-reactive protein and IL-6 levels. Thus far, the intravenous transplantation of MSCs has been shown to be effective for the treatment of patients with COVID-19 pneumonia, especially for the patients in critical condition.

Exosomes derived from MSCs have been studied in clinical trials for treating severely compromised COVID-19 patients[104,105,109]. Exosomes (ExoFlo™) derived from allogeneic bone marrow MSCs in a single 15 mL dose were evaluated in a 24-patient trial[113] for both safety and efficacy from days 1 to 14 post-treatment. No adverse events were observed; a survival rate of 83% was observed; 71 patents recovered, 13% remained critically ill though stable, and 16% patients expired for reasons unrelated to the treatment. Overall, after one treatment, patients’ clinical status and oxygenation improved with an average pressure of arterial oxygen to fraction of inspired oxygen.
ratio (PaO₂/FiO₂) increase of 192%. Laboratory values revealed significant improvements in absolute neutrophil count and lymphopenia with average CD3+, CD4+, and CD8+ lymphocyte counts increasing by 46%, 45%, and 46%, respectively. Likewise, acute phase reactants declined, with mean C-reactive protein, ferritin, and D-dimer reduction of 77%, 43%, and 42%, respectively. The study demonstrated the excellent safety profile and capacity to restore oxygenation, downregulate cytokine storm, and reconstitute immunity. Exosome derived from MSCs is a promising therapeutic candidate for severely compromised COVID-19 patients.

CONCLUSION

The social burden of COVID-19 is growing with the global pandemic. However, there is no effective or curative therapy for COVID-19, and preventive vaccines, other than the vaccine recently approved in Russia, but for which there is limited information, are still under development and will not be available until next year. The most recent clinical trials with MSCs may fulfill the unmet medical need of COVID-19, to reduce the related ARDS and cytokine storm. There are several issues that need to be addressed in order to move forward: dose, delivery times, type of MSCs, efficacy and cost-effectiveness. An understanding of all facets of MSCs and pathomechanism of COVID-19 is necessary to fully translate the MSCs therapy into a meaningful treatment for COVID-19. The next therapeutic strategies may focus on a combination approach using two or more types of MSCs, certain type of MSCs, and immune-based therapies or antiviral therapies to achieve maximal therapeutic efficacy.

REFERENCES

1 Guarner J. Three Emerging Coronaviruses in Two Decades. Am J Clin Pathol 2020; 153: 420-421 [PMID: 32053148 DOI: 10.1093/ajcp/aqaa029]
2 Jung YJ, Park YY, Huh JW, Hong SB. The effect of human adipose-derived stem cells on lipopolysaccharide-induced acute respiratory distress syndrome in mice. *Ann Transl Med* 2019; 7: 674 [PMID: 31930075 DOI: 10.21037/atm.2019.10.48]

3 Chen CH, Chen YL, Sung PH, Sun CK, Chen KH, Chen YL, Huang TH, Lu HI, Lee FY, Sheu JJ, Chung SY, Lee MS, Yip HK. Effective protection against acute respiratory distress syndrome/sepsis injury by combined adipose-derived mesenchymal stem cells and preactivated disaggregated platelets. *OncoTarget* 2017; 8: 82415-82429 [PMID: 29137274 DOI: 10.18632/oncotarget.19312]

4 Lu H, Cook T, Poirier C, Merfeld-Clauss S, Petracek I, March KL, Bogatcheva NV. Pulmonary Retrieval of Adipose Stromal Cells Following Intravenous Delivery Is Markedly Altered in the Presence of ARDS. *Cell Transplant* 2016; 25: 1635-1643 [PMID: 26609693 DOI: 10.3727/096368915X690189]

5 Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, Deng K, Zhang L, Zou B, Cheng B, Xu J. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. *Respir Res* 2014; 15: 39 [PMID: 24708472 DOI: 10.1186/1465-9221-15-39]

6 Lu Z, Chang W, Meng S, Xu X, Xie J, Guo F, Yang Y, Qiu H, Liu L. Mesenchymal stem cells induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to alleviate acute lung injury. *Stem Cell Res Ther* 2019; 10: 372 [PMID: 31801626 DOI: 10.1186/s13287-019-1488-2]

7 Silva JD, de Castro LL, Braga CL, Oliveira GP, Trivelin SA, Barbosa-Junior CM, Morales MM, Dos Santos CC, Weiss DJ, Lopes-Pacheco M, Cruz FF, Rocco PRM. Mesenchymal Stromal Cells Are More Effective Than Their Extracellular Vesicles at Reducing Lung Injury Regardless of Acute Respiratory Distress Syndrome Etiology. *Stem Cells Int* 2019; 2019: 862684 [PMID: 31351026 DOI: 10.1155/2019/862684]

8 Xu AL, Rodriguez LA 2nd, Walker KP 3rd, Mohammadipoor A, Kamucheka RM, Cancio LC, Batchinsky AI, Anete B. Mesenchymal Stem Cells Reconditioned in Their Own Serum Exhibit Augmented Therapeutic Properties in the Setting of Acute Respiratory Distress Syndrome. *Stem Cells Transl Med* 2019; 8: 1092-1106 [PMID: 31219247 DOI: 10.1002/sctm.18-0236]

9 Cardenes N, Aranda-Valderama P, Carney JP, Sellares Torres J, Alvarez D, Kocyildirim E, Wolfram Smith JA, Ting AE, Lagazzi L, Yu Z, Mason S, Santos E, Lopresti BJ, Rojas M. Cell therapy for ARDS: efficacy of endobronchial versus intravenous administration and biodistribution of MAPCs in a large animal model. *BMJ Open Respir Res* 2019; 6: e000308 [PMID: 30713713 DOI: 10.1136/bmjresp-2018-000308]

10 Li L, Dong L, Zhang J, Guo F, Hui J, Yan J. Mesenchymal stem cells with downregulated Hippo signaling attenuate lung injury in mice with lipopolysaccharide-induced acute respiratory distress syndrome. *Int J Mol Med* 2019; 43: 1241-1252 [PMID: 30628652 DOI: 10.3892/ijmm.2018.4047]

11 Mokbrer Dezfoli MR, Jabbari Fakhri M, Sadeghian Chaleshori S, Dehghan MM, Vajhi A, Mokhtari R. Intrapulmonary autologous transplant of bone marrow-derived mesenchymal stromal cells improves lipopolysaccharide-induced acute respiratory distress syndrome in rabbit. *Crit Care* 2018; 22: 353 [PMID: 30572913 DOI: 10.1186/s13054-018-2272-x]

12 Schwede M, Wilfong EM, Zemans RL, Lee PJ, Dos Santos C, Fang X, Matha MA. Effects of bone marrow-derived mesenchymal stromal cells on gene expression in human alveolar type II cells exposed to TNF-α, IL-1β, and IFN-γ. *Physiol Rep* 2018; 6: e13831 [PMID: 30136410 DOI: 10.14814/phy2.13831]

13 Masterson C, Devaney J, Horie S, O'Flynn L, Deedigan L, O'Toole D, Laffey JG. Syndecan-2-positive, Bone Marrow-Derived Human Mesenchymal Stromal Cells Attenuate Bacterial-induced Acute Lung Injury and Enhance Resolution of Ventilator-induced Lung Injury in Rats. *Anesthesiology* 2018; 129: 502-516 [PMID: 29979191 DOI: 10.1097/ALN.0000000000002272]

14 Park J, Jeong S, Park K, Yang K, Shin S. Expression profile of microRNAs following bone marrow-derived mesenchymal stem cell treatment in lipopolysaccharide-induced acute lung injury. *Exp Ther Med* 2018; 15: 5495-5502 [PMID: 29904439 DOI: 10.3892/etm.2018.6118]

15 Pedraza L, Cunha AA, Luft C, Nunes NK, Schimitz F, Gassen RB, Breda RV, Donadio MV, de Souza Wyse AT, Pitreza PMC, Rosa JL, de Oliveira JR. Mesenchymal stem cells improve survival in LAP-induced acute lung injury acting through inhibition of NETs formation. *J Cell Physiol* 2017; 232: 3552-3564 [PMID: 28123921 DOI: 10.1002/jcp.22816]

16 Yang Y, Hu S, Xu X, Li J, Liu A, Han J, Liu S, Liu L, Qiu H. The Vascular Endothelial Growth Factors-Expressing Character of Mesenchymal Stem Cells Plays a Positive Role in Treatment of Acute Lung Injury In Vivo. *Mediators Inflamm* 2016; 2016: 2347938 [PMID: 27313398 DOI: 10.1155/2016/2347938]

17 Moodley Y, Sturm M, Shaw K, Shimbori C, Tan DB, Kolb M, Graham R. Human mesenchymal stem cells attenuate early damage in a ventilated pig model of acute lung injury. *Stem Cell Res* 2016; 17: 25-31 [PMID: 27233195 DOI: 10.1016/j.scr.2016.05.005]

18 Hayes M, Curley GF, Masterson C, Devaney J, O'Toole D, Laffey JG. Mesenchymal stem cells are more effective than the MSCs secretome in diminishing injury and enhancing recovery following ventilator-induced lung injury. *Intensive Care Med Exp* 2015; 3: 29 [PMID: 26472334 DOI: 10.1186/s40635-015-0065-y]

19 Monsel A, Zhu YG, Gemai S, Hao Q, Hu S, Rouby JJ, Rosenzweig M, Matha MA, Lee JW. Therapeutic Effects of Human Mesenchymal Stem Cell-Derived Microvesicles in Severe Pneumonia in Mice. *Am J Respir Crit Care Med* 2015; 192: 324-336 [PMID: 26067592 DOI: 10.1164/rccm.201410-1765OC]

20 Hao Q, Zhu YG, Monsel A, Gemai S, Lee T, Xu F, Lee JW. Study of Bone Marrow and Embryonic Stem Cell-Derived Human Mesenchymal Stem Cells for Treatment of Escherichia coli Endotoxin-Induced Acute Lung Injury in Mice. *Stem Cells Transl Med* 2015; 4: 832-840 [PMID: 25995518 DOI: 10.9664/stem.2015.0006]

21 Devaney J, Horie S, Masterson C, Eilllman S, Barry F, O'Brien T, Curley GF, O'Toole D, Laffey JG. Human mesenchymal stem cells decrease the severity of acute lung injury induced by E. coli in the rat. *Thorax* 2015; 70: 625-635 [PMID: 25986435 DOI: 10.1136/thoraxjnl-2015-206813]

22 Assmusser S, Ito H, Traber DL, Lee JW, Cox RA, Hawkins HK, McAuley DF, McKenna DH, Traber LD, Zhao H, Wilson J, Hernandez DN, Prough DS, Liu KD, Matha MA, Enklibatkar P. Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. *Thorax* 2014;
Lin F et al. MSC therapy for COVID-19

69: 819-825 [PMID: 24891325 DOI: 10.1136/thoraxjnl-2013-204980]

23 Shalaby SM, El-Shal AS, Abd-Allah SH, Selim AO, Selim SA, GoudaZA, Abd El Motteleb DM, Zafally HE, El-Assar HM, Abdelazim S. Mesenchymal stromal cell injection protects against oxidative stress in Escherichia coli-induced acute lung injury in mice. Cytoterapy 2014; 16: 764-775 [PMID: 24525173 DOI: 10.1016/j.cyt.2013.12.006]

24 Busto ML, Huleiel L, Meyer EM, Donnenberg AD, Donnenberg VS, Sicuria JD, Möz L, Mcvery BJ, Ellis BM, Kaminski N, Rojas M. Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. Stem Cells Transl Med 2013; 2: 884-895 [PMID: 24089414 DOI: 10.5966/sectm.2013-0033]

25 Rojas M, Parker RE, Thorn N, Corredor C, Iyer SS, Bueno M, Möz L, Cardenes N, Mora AL, Steenkon AA, Brigham KL. Infusion of freshly isolated autologous bone marrow derived mononuclear cells prevents endotoxin-induced lung injury in an ex vivo perfused swine model. Stem Cell Res Ther 2013; 4: 26 [PMID: 23497755 DOI: 10.1186/s13287-013-0174]

26 Yan X, Fu X, Jia Y, Ma X, Tao J, Yang T, Ma H, Liang X, Liu X, Yang J, Wil J. Nrf2/Keap1 ARE Signaling Mediated an Antioxidative Protection of Human Placental Mesenchymal Stem Cells of Fetal Origin in Alveolar Epithelial Cells. Oxid Med Cell Longev 2019; 2019: 2654910 [PMID: 31217836 DOI: 10.1155/2019/2654910]

27 Cui P, Xin H, Yao Y, Xiao S, Zhu F, Gong Z, Tang Z, Zhan Q, Qin W, Lai Y, Li X, Tong Y, Xia Z. Human ammonium-derived mesenchymal stem cells alleviate lung injury induced by white smoke inhalation in rats. Stem Cell Res Ther 2016; 9: 101 [PMID: 29650044 DOI: 10.1186/s13287-018-0856-7]

28 Zhang S, Jiang W, Ma L, Liu Y, Zhang X, Wang S. Nrf2 transfection enhances the efficacy of human amniotic mesenchymal stem cells to repair lung injury induced by lipopolysaccharide. J Cell Biochem 2018; 119: 1627-1636 [PMID: 28905450 DOI: 10.1002/jcb.2622]

29 Huang Z, Liu H, Zhang X, Wen G, Zhu C, Zhao Y, Niu W, Qin Y, Chen H, Bai C, Liu G. Transcriptomic analysis of lungs tissues after hUC-MSCs and FTY720 treatment of lipopolysaccharide-induced acute lung injury in mouse models. Int Immunopharmacol 2018; 63: 26-34 [PMID: 30064040 DOI: 10.1016/j.intimp.2018.06.016]

30 Xuan YY, Wu YY, Xie YL, Chu YJ, Li GX, Wang LP. Human Mesenchymal Stem/Stromal Cells From Human Umbilical Cord Ameliorate Acute Respiratory Distress Syndrome in Rats: Factors to Consider. Crit Care Med 2017; 45: e736-e737 [PMID: 28622233 DOI: 10.1097/CMM.0000000000002401]

31 Lee FY, Chen KH, Wallace CG, Sung PH, Shue JJ, Chung SY, Lu HI, Ko SF, Sun CK, Chiang HJ, Chang HW, Lee MS, Yip HK. Xenogenic human umbilical cord-derived mesenchymal stem cells reduce mortality in rats with acute respiratory distress syndrome complicated by sepsis. Oncotarget 2017; 8: 45626-45642 [PMID: 28484089 DOI: 10.18632/oncotarget.17320]

32 Zhu H, Xiong Y, Xia Y, Zhang R, Tian D, Wang T, Dai J, Wang L, Yao H, Jiang H, Yang K, Liu E, Shi Y, Fu Z, Gao L, Zou L. Therapeutic Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Acute Lung Injury Mice. Sci Rep 2017; 7: 39889 [PMID: 28051154 DOI: 10.1038/srep39889]

33 Curley GF, Jerkic M, Dixon S, Hogan G, Masterson C, O’Toole D, Devaney J, Laffey JG. Cryopreserved, Xeno-Free Human Umbilical Cord Stromal Cells Reduce Lung Injury Severity and Behavioral Burden in Rodent Escherichia coli-Induced Acute Respiratory Distress Syndrome. Crit Care Med 2017; 45: e202-e212 [PMID: 27861182 DOI: 10.1097/CCM.0000000000002073]

34 Chang Y, Park SH, Huh JW, Lim CM, Koh Y, Hong SB. Intratracheal administration of umbilical cord blood-derived mesenchymal stem cells in a patient with acute respiratory distress syndrome. J Korean Med Sci 2014; 29: 438-440 [PMID: 24616596 DOI: 10.3346/jkms.2014.29.3.438]

35 Moodley Y, Atienza D, Manuelpillai U, Samuel CS, Tchongue J, Flamcheran S, Boyd R, Traunson A. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Transl Res 2009; 175: 303-313 [PMID: 19479992 DOI: 10.2353/ajtr.2009.090029]

36 Xiang B, Chen L, Wang X, Zhao Y, Wang Y, Xiang C. Transplantation of Menstrual Blood-Derived Mesenchymal Stem Cells Promotes the Repair of LPS-Induced Acute Lung Injury. Int J Mol Sci 2017; 18 [PMID: 28346367 DOI: 10.3390/ijms18040689]

37 Wang L, Shi M, Tong L, Wang J, Ji S, Bi J, Chen C, Jiang J, Bai C, Zhou J, Song Y. Lung-Resident Mesenchymal Stem Cells Promote Repair of LPS-Induced Acute Lung Injury via Regulating the Balance of Regulatory T cells and Th17 cells. Inflammation 2019; 42: 199-210 [PMID: 30187337 DOI: 10.1007/s10753-018-0884-6]

38 Silva JD, Lopes-Pacheco M, Paz AHR, Cruz FF, Melo EB, de Oliveira MV, Xisto DG, Capelozzi VL, Morales MM, Pelosi P, Corne-Lima E, Rocco PRM. Mesenchymal Stem Cells From Bone Marrow, Adipose Tissue, and Lung Tissue Differentially Mitigate Lung and Distal Organ Damage in Experimental Acute Respiratory Distress Syndrome. Crit Care Med 2018; 46: e132-e140 [PMID: 29116998 DOI: 10.1097/CCM.0000000000002833]

39 Su YY, Lin CS, Hung SC, Yang KY. Mesenchymal Stem Cell-Conditioned Medium Induces Neutrophil Apoptosis Associated with Inhibition of the NF-κB Pathway in Endotoxin-Induced Acute Lung Injury. Int J Mol Sci 2019; 20 [PMID: 31060326 DOI: 10.3390/ijms20092208]

40 Mohammadipoor A, Antebi B, Batchinsky AI, Cancio LC. Therapeutic potential of products derived from mesenchymal stromal/stem cells in pulmonary disease. Respir Res 2018; 19: 218 [PMID: 30413158 DOI: 10.1186/s12931-018-0921-x]

41 Lee JH, Park J, Lee JW. Therapeutic use of mesenchymal stem-cell-derived extracellular vesicles in acute lung injury. Transfusion 2019; 59: 876-883 [PMID: 30383895 DOI: 10.1111/trf.14838]

42 Abreu SC, Weiss DJ, Rocco PR. Extracellular vesicles derived from mesenchymal stromal cells: a therapeutic option in respiratory diseases? Stem Cell Res Ther 2016; 7: 53 [PMID: 27053636 DOI: 10.1186/s12877-016-0317-0]

43 Monsel A, Zhu YG, Gadapati V, Lim H, Lee JW. Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases. Expert Opin Biol Ther 2016; 16: 859-871 [PMID: 27011289 DOI: 10.1517/14712598.2016.1170804]

44 Liu FB, Lin Q, Liu ZW. A study on the role of apoptotic human umbilical cord mesenchymal stem cells in...
bleomycin-induced acute lung injury in rat models. *Eur Rev Med Pharmacol Sci* 2016; 20: 969-982 [PMID: 27071019].

Chen J, Li Y, Hao H, Li C, Du Y, Hu Y, Li J, Liang Z, Li C, Liu J, Chen L. Mesenchymal Stem Cell Conditioned Medium Promotes Proliferation and Migration of Alveolar Epithelial Cells under Septic Conditions In Vitro via the JNK, P38 Signaling Pathway. *Cell Physiol Biochem* 2015; 37: 1830-1846 [PMID: 26584283] DOI: 10.1159/000438545.

Ionescu I, Byrne RN, van Haafeten T, Vadvile A, Alphonse RS, Rey-Parru GI, Weissmann G, Hall A, Eaton F, Thébaud B. Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action. *Am J Physiol Lung Cell Mol Physiol* 2012; 303: L967-L977 [PMID: 23025971] DOI: 10.1152/alappl.00441.2011.

Zhao R, Su Z, Wu J, Ji HL. Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis. *Oncotarget* 2017; 8: 30511-30523 [PMID: 28436222] DOI: 10.18632/oncotarget.15426.

Cheng SL, Lin CH, Yao CL. Mesenchymal Stem Cell Administration in Patients with Chronic Obstructive Pulmonary Disease: State of the Science. *Stem Cells Int* 2017; 2017: 8916570 [PMID: 28301154] DOI: 10.1155/2017/8916570.

Aturri S, Manchikanti L, Hirsch JA. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. *Pain Physician* 2020; 23: E71-E83 [PMID: 32214236].

Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, Zhao Y, Yin H, He X, Gao Z, Wang Y, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A, Chakrabarti S, Min KJ, Ellis-Hughes G, Caruso C, Jin K, Zhao RC. Transplantation of ACE2: Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. *Aging Dis* 2020; 11: 216-228 [PMID: 32255737] DOI: 10.14336/AD.2020.0228.

Letho M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol* 2020; 5: 562-569 [PMID: 32094589] DOI: 10.1038/s41564-020-0688-x.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhuan, China. *Lancet* 2020; 395: 497-506 [PMID: 31986264] DOI: 10.1016/S0140-6736(20)30183-5.

Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. *Clin Immunol* 2020; 215: 108427 [PMID: 32325252] DOI: 10.1016/j.clim.2020.108427.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020; 8: 420-422 [PMID: 32085846] DOI: 10.1016/S2213-2600(20)30076-X.

Colamarino ABL, Lemieux W, Bifisha P, Nicoletti S, Chakravarti N, Sanz J, Roméro H, Selleri S, Béland K, Guitot M, Tremblay-Laganière C, Dicaire R, Barreiro L, Lee DA, Verhoeyen E, Haddad E. Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivirus. *Front Immunol* 2019; 10: 2873 [PMID: 31921138] DOI: 10.3389/fimmu.2019.02873.

Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, Cai J, Li X, Kang W, Deng D, Lu W, Yu D, He L, Yao K. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. *J Pathol* 2003; 200: 282-289 [PMID: 12845627] DOI: 10.1002/path.1440.

Dug DL, Al Hosani F, Keating MK, Gerber SI, Jones TL, Metcalfe MG, Tong S, Tao Y, Alami NN, Haynes LM, Mueei MA, Abdel-Wareth L, Uyeki TM, Swerdlow DL, Barakat M, Zaki SR. Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014. *Am J Pathol* 2016; 186: 652-658 [PMID: 26857507] DOI: 10.1016/j.ajpath.2015.10.024.

Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Infection in Two Patients With Lung Cancer. *J Thorac Oncol* 2020; 15: 700-704 [PMID: 3214094] DOI: 10.1016/j.jtho.2020.02.010.

Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, Xiao SY. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. *Mod Pathol* 2020; 33: 1087-1014 [PMID: 32291399] DOI: 10.1038/s41379-020-0536-x.

Barton LM, Duval EJ, Strobeg E, Ghosh S, Mukhopadhyay S. COVID-19 Autopsies, Oklahoma, United States. *Am J Clin Pathol* 2020; 153: 725-733 [PMID: 32275742] DOI: 10.1093/ajcp/aqaa062.

Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. *Transl Res* 2020; 220: 1-13 [PMID: 32299776] DOI: 10.1016/j.trsl.2020.04.007.

Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. *Nat Rev Immunol* 2012; 12: 383-396 [PMID: 22531326] DOI: 10.1038/nri3209.

Jiang B, Yan L, Wang X, Li E, Murphy K, Vaccaro K, Li Y, Xu RH. Concise Review: Mesenchymal Stem Cells Derived from Human Pluripotent Cells, an Unlimited and Quality-Controllable Source for Therapeutic Applications. *Stem Cells* 2019; 37: 572-581 [PMID: 30561809] DOI: 10.1002/stem.2964.

Campagnoni C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. *Blood* 2001; 98: 2396-2402 [PMID: 11588036] DOI: 10.1182/blood.v98.8.2396.

Carlotti F, Zaldambide A, Loomans CJ, van Rossebergen E, Engelse M, de Koning EJ, Hoeven RC. Isolated human inlets contain a distinct population of mesenchymal stem cells. *Islets* 2010; 2: 164-173 [PMID: 21099310] DOI: 10.4161/islt.2.3.14489.

Nandy SB, Mohanty S, Singh M, Behari M, Airan B. Fibroblast Growth Factor-2 alone as an efficient
Human bone marrow mesenchymal stem cells to dopaminergic neurons. J Biomed Sci 2014; 21: 83 [PMID: 25248378 DOI: 10.1186/s12929-014-0083-1]

Armänä A, Gandia C, Bartual M, García-Verdugo JM, Lleo E, Mirabet V, Llop M, Barea J, Montero JA, Sepulveda P. Cardiac differentiation is driven by NKX2.5 and GATA4 nuclear translocation in tissue-specific mesenchymal stem cells. Stem Cells Dev 2009; 18: 907-918 [PMID: 19883250 DOI: 10.1089/scd.2008.0292]

Liu J, Wang Y, Wu Y, Ni B, Liang Z. Sodium butyrate promotes the differentiation of rat bone marrow mesenchymal stem cells to smooth muscle cells through histone acetylation. PLoS One 2014; 9: e116183 [PMID: 25548915 DOI: 10.1371/journal.pone.0116183]

Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: crucial role of MSCs-derived prostaglandin E2. Blood 2009; 113: 6576-6583 [PMID: 19398717 DOI: 10.1182/blood-2008-02-209343]

Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W, Roberts AL, Le AD, Shi S, Shao C, Shi Y. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 2010; 184: 2321-2328 [PMID: 20130212 DOI: 10.4049/jimmunol.0902023]

Kriegsmann K, Kriegsmann M, Cremer M, Schmitt M, Dreger P, Goldschmidt H, Müller-Tidow C, Hundemer M. Cell-based immunotherapy approaches for multiple myeloma. Br J Cancer 2019; 120: 38-44 [PMID: 30518815 DOI: 10.1038/s41416-018-0346-9]

Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol 2010; 184: 5885-5894 [PMID: 20382885 DOI: 10.4049/jimmunol.0903143]

Sotopoulos PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85 [PMID: 16999908 DOI: 10.1634/stemcells.2004-0359]

Djouad F, Charbonnier LM, Bouffet C, Louis-Plence P, Bony C, Apparailly F, Cantos C, Jorgensen C, Noël D. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-2032 [PMID: 17510220 DOI: 10.1634/stemcells.2006-0548]

Najar M, Rouas R, Raievic G, Boulker H, Lewalle P, Meuleman N, Bron D, Toungouz M, Marquet S, Laganeux L. Mesenchymal stromal cells can suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 2009; 11: 570-583 [PMID: 19565371 DOI: 10.1080/14653240903079377]

Chabannes D, Hill M, Merieu E, Rossignol J, Brion R, Soulilou JP, Anegon I, Coturi MC. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007; 110: 3691-3694 [PMID: 17684137 DOI: 10.1182/blood-2007-02-075481]

Nasef A, Mazurier C, Bouchet S, François S, Chapel A, Thierry D, Gorin NC, Fouillard L. Lymphoma inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol 2008; 253: 16-22 [PMID: 18639869 DOI: 10.1016/j.cellimm.2008.06.002]

Rizzo R, Campioni D, Stignani M, Melchiorri L, Bagnara GP, Bonsi L, Alviano F, Lanzoni G, Moretti S, Cuneo A, Lanza F, Baricordi OR. A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy 2008; 10: 364-375 [PMID: 18574769 DOI: 10.1080/14653240802105299]

Tyndall A, van Laar JM. Stem cell transplantation and mesenchymal cells to treat autoimmune diseases. Press Med 2016; 45: e159-e169 [PMID: 27256975 DOI: 10.1016/j.jpm.2016.05.002]

Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamao T, Cai T, Chen W, Sun L, Shi S. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand – FAS-mediated T cell apoptosis. Stem Cell 2012; 2012: 54-55 [PMID: 22542159 DOI: 10.1634/stemcells.2012-03.907]

Wang H, Qi F, Dai X, Tian W, Liu T, Han H, Zhang B, Li H, Zhang Z, Du C. Requirement of B7-H1 in mesenchymal stem cells for immune tolerance to cardiac allografts in combination therapy with rapamycin. Transpl Immunol 2014; 31: 65-74 [PMID: 24978830 DOI: 10.1016/j.trim.2014.06.005]

Gazdic M, Markovic BS, Arsenijevic A, Jovicic N, Acovic A, Harrell CR, Fellabaum C, Djonov V, Arsenijevic N, Lukic ML, Volarevic V. Crossstalk between mesenchymal stem cells and T regulatory cells is crucially important for the attenuation of acute liver injury. Liver Transpl 2018; 24: 687-702 [PMID: 29500914 DOI: 10.1002/lt.25049]

Luz-Crawford P, Kurte M, Bravo-Alegria J, Contreras R, Nova-Lamperti E, Tejedor G, Noël D, Jorgensen C, Figueroa F, Djouad F, Carrion F. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther 2013; 4: 65 [PMID: 23734780 DOI: 10.1186/scrt16]

Mohammadpour H, Pourfathollah AA, Zarif MN, Tahoori MT. TNF-α modulates the immunosuppressive effects of MSCs on dendritic cells and T cells. Int Immunopharmacol 2015; 28: 1009-1017 [PMID: 26303769 DOI: 10.1016/j.intimp.2015.07.045]

Yan Z, Zhuansun Y, Liu G, Chen R, Li J, Ran P. Mesenchymal stem cells suppress T cells by inducing apoptosis and through PD-1/B7-H1 interactions. Immuno Lett 2014; 162: 248-255 [PMID: 25281059 DOI: 10.1016/j.imlet.2014.09.013]

Chinnadurai R, Copland IB, Patel SR, Galipeau J. IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells. J Immunol 2014; 192: 1491-1501 [PMID: 24403533 DOI: 10.4049/jimmunol.1301828]

Jang IK, Yoon HH, Yang MS, Lee JE, Lee DH, Lee MW, Kim DS, Park JE. B7-H1 inhibits T cell proliferation through MHC class II in human mesenchymal stem cells. Transplant Proc 2014; 46: 1638-1641 [PMID: 24935340 DOI: 10.1016/j.proceed.2013.12.059]

Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843 [PMID: 11986244 DOI: 10.1182/blood.v99.10.3838]
Mesenchymal Stem Cells as Treatment for Severe COVID-19.

Sengupta V, O'Driscoll L. Today 2020; 10.1186/s13054-020-03142-8

In patients with severe COVID-19 pneumonia.

Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.

Zhang Y, Qin H, Takamura M, Terai S. Therapeutic potential of mesenchymal stem cells and their exosomes in severe coronavirus disease 2019 (COVID-19) cases.

Natsui K, Takeda N, Yoshida Y, Yamazaki F, Kojima Y, Watanabe Y, Kimura N, Tominaga K, Kamimura Tsuchiya A. Mediators of Anti-Inflammatory Effects: Endorsement of Macrophage Polarization. Stem Cells Transl Med 2017; 6: 1018-1028 [PMID: 28186708] DOI: 10.1002/sctm.16-0363

Takizawa N, Okubo N, Kano M, Chosa N, Mikami T, Suzaki K, Yokota S, Ibi M, Ohtsuka M, Taira M, Yaegashi T, Ishisaki A, Kyakumoto S. Bone marrow-derived mesenchymal stem cells propagate immunosuppressive/anti-inflammatory macrophages in cell-to-cell contact-independent and -dependent manners under hypoxic culture. Exp Cell Res 2017; 358: 411-420 [PMID: 28712928] DOI: 10.1016/j.yexcr.2017.07.014

Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107: 1484-1490 [PMID: 16239427] DOI: 10.1182/blood-2005-07-2775

Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, Ottonello L, Pistoia V. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 2008; 26: 151-162 [PMID: 17932421] DOI: 10.1634/stemcells.2007-0416

Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4210-4216 [PMID: 15920669] DOI: 10.1182/blood-2004-02-0356

Putra A, Ridwan FB, Putridewi AI, Kustiyah AR, Wirastuti K, Sadyah NAC, Rosdiana I, Munir D. The Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. J Transl Med 2020; 18: 203 [PMID: 32423449] DOI: 10.1186/s12967-020-02380-2

Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353: 1685-1693 [PMID: 16236739] DOI: 10.1056/NEJMoa050333

Golchin A, Seyedjafari E, Ardeshirlyajimi A. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. Stem Cell Rev Rep 2020; 16: 427-433 [PMID: 32381052] DOI: 10.1007/s12967-020-00973-6

Liu S, Peng D, Qiu H, Yang K, Fu Z, Zou L. Mesenchymal stem cells as a potential therapy for COVID-19. Stem Cell Res Ther 2020; 11: 169 [PMID: 32366290] DOI: 10.1186/s13287-020-01678-8

Rogers CJ. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. J Transl Med 2020; 18: 203 [PMID: 32423449] DOI: 10.1186/s12967-020-02380-2

Tschiya A, Takeuchi S, Iwasaka S, Chargui S, Chen Y, Luo X, He X, Zhang Y, Wang J. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia. Crit Care 2020; 24: 420 [PMID: 32653043] DOI: 10.1186/s13054-020-03142-8

O'Driscoll L. Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment. Drug Discov Today 2020; 25: 1124-1125 [PMID: 32387262] DOI: 10.1016/j.drudis.2020.04.022

Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev 2020; 29: 747-754 [PMID: 32380908] DOI: 10.1089/scd.2020.0880
